Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Morrisons has announced it will shut 17 of its convenience stores across the UK in the coming weeks, with most closures taking place on Wednesday, 16 April.
According to reporting from The Sun, 16 Morrisons Daily branches will close on 16 April, while a further store in Haxby, North Yorkshire, will close on 14 May. In addition, 11 of the affected branches include Post Office counters, which are also scheduled to shut between 9 April and 14 May.
Branches set for closure include locations in Exeter, Tonbridge, and Worle. Morrisons Daily stores operate as smaller convenience outlets, typically offering extended opening hours compared to the supermarket's main stores.
The closures were first announced last month, alongside a broader restructuring of Morrisons’ operations. The supermarket confirmed it would also be shutting 52 of its in-store cafés, putting approximately 365 jobs at risk. Furthermore, it will close 35 meat counters, 35 fish counters, four pharmacies, and all 18 of its Market Kitchen food courts across its estate.
Morrisons, which employs around 95,000 people in its supermarkets and an additional 1,600 at its Daily stores, has faced ongoing challenges in recent years. The chain has experienced a decline in its market share and now commands just 8.5 per cent of the UK grocery market.
As part of its response to these difficulties, Morrisons has set a new medium-term savings target of £1 billion. The company revealed it had achieved £56 million in cost savings during the three months leading to 26 January and expects to deliver the remainder of its previous £700 million target by the second quarter of the year.
Chief Executive Rami Baitiéh highlighted the pressures facing the business, pointing to what he described as an "avalanche of costs" affecting the sector. He cited changes to National Insurance contributions and increases to the minimum wage as some of the major cost challenges impacting operations.
In a statement to The Sun, Morrisons said: "Morrisons has made the difficult decision to close some Morrisons Daily stores, some of which contain Post Offices. We fully recognise the inconvenience this will cause for our customers and apologise for the short notification as these branches close between 9 April and 14 May."
Baitiéh also addressed the closures when announcing the changes last month, saying: "The changes we are announcing today are a necessary part of our plans to renew and reinvigorate Morrisons and enable us to focus our investment into the areas that customers really value and that can play a full part in our growth."
The closures form part of a wider effort by Morrisons to streamline its operations and focus resources on core areas of the business. The move comes as supermarkets across the UK continue to face intense competition from discount retailers such as Aldi and Lidl, as well as ongoing economic pressures affecting consumer spending.
While Morrisons' overall restructuring plan aims to strengthen its position in a challenging market, the immediate impact will see significant changes to the retailer’s convenience and in-store offerings.
The company has not yet confirmed whether any further closures are expected later this year.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.